Loren Data's SAM Daily™

FBO DAILY ISSUE OF MAY 12, 2002 FBO #0161
SOLICITATION NOTICE

68 -- Catalyzed Signal Amplification

Notice Date

5/10/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20047-NG
 

Response Due

5/24/2002
 

Archive Date

6/8/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, rasmusc@mail.nih.gov
 

Description

The National Cancer Institute (NCI), Division of Clinical Sciences (DCS), Laboratory of Pathology intends to procure Catalyzed Signal Amplification Kits 15 mL, catalog number K150011, from DAKO Corporation, 22 North Milpas Street, Santa Barbara, California 93103. The North American Industry Classification System code is 422210 and the business size standard is 100 employees. The "Tissue Proteomics Initiative" (TPI) is an entity that exists between the Center for Biologics and Research (CBER), Food and Drug Administration (FDA) and the Center for Cancer Research, National Cancer Institute. It is the advancement of common research interests shared by CBER and NCI in the application and development of proteomic technology to the diagnosis and treatment of human cancer, development of proteomic tools that can detect and predict therapeutic efficacy and toxicity, further evaluate licensed and experimental drugs and biologics, and build upon the ongoing work emanating from the TPI. The Catalyzed Signal Amplification System kit from DAKO is used as the mechanism for detecting the protein that have been immobilized on the surface of reverse phase protein arrays. Reverse phase protein microarrays are prepared by applying picaliters of a tissue extract prepared from the cells procured by laser capture microdissection of human tissue. The proteins of interest are detected by the catalyzed signal amplification kits developed and distributed by DAKO Corp. This system is an extremely sensitive immunochemical staining procedure incorporating a signal amplification method based on the peroxidase-catalyzed deposition of a biotinylated phenolic compound followed by secondary reaction with streptavidin peroxidase. Comparisons to standard labeled streptavidin biotin methods have shown the DAKO CSA System to be on the order of 50-fold greater in sensitivity. Furthermore, the CSA system is optimized for use with the DAKO Autostainer, a sophisticated immunohistochemical staining system already in place in this laboratory. BASE PERIOD (Year 1): The base period of performance will begin in May 2002 and end October 31, 2002. During this period, NCI requires a minimum of 36 CSA kits 15 mL catalog number K150011 up to a maximum of 60 CSA kits15 mL catalog number K150011. OPTION 1 (Year 2): The optional period of performance will begin November 1, 2002 and end October 31, 2003. During this period, NCI requires a minimum of 78 CSA kits 15 mL catalog number K150011 and a maximum of 208 CSA kits 15 mL catalog number K150011. OPTION 2 (Year 3): The optional period of performance will begin November 1, 2003 and end October 31, 2004. During this period, NCI requires a minimum of 78 CSA kits 15 mL catalog number K150011 and a maximum of 208 CSA kits 15 mL catalog number K150011. Changing variables at this time will interrupt correct interpretation of the current experiment in progress. As stated above, this system is an extremely sensitive immunochemical staining procedure. This procedure allows detection of extremely small quantities of target proteins as would be seen in very small numbers of tissue cells. This notice of intent is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above specifications described herein. Capability statements must propose the option(s) in order for the capability statement to be considered for review. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington, D.C. time) on May 24, 2002. If you have any questions, please contact Malinda Holdcraft Purchasing Agent, via electronic mail at holdcram@exchange.nih.gov. If submitting capability statements, one original and two copies are required. Capability statements must be mailed to the following address: Malinda Holdcraft, NIH/NCI/RCB, 6120 Executive Blvd. Suite 6072, Rockville, Maryland 20852-7194. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed copies of capability statements will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD 20892

Zip Code: 20892

Country: USA
 

Record

SN00075047-W 20020512/020510213113 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |